Drug Trial Radar · NCT06338657
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Apr 1, 2024
Primary completion
Sep 3, 2025
Study completion Sep 9, 2025
Sponsor
- Lead sponsor
- University of Southern CaliforniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This study is being done to help identify future treatment options and better understand how to improve outcomes of patients with head and neck cancers after surgery.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT scan
Magnetic Resonance ImagingProcedure
Undergo MRI
PEOX-based Polymer Encapsulated Paclitaxel FID-007Drug
Given IV
Tumor ResectionProcedure
Undergo surgical resection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the phenotypical and functional changes of different T cell subsets within the tumor microenvironment after treatment with FID-007Time frame: Baseline up to 30 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.